Comprehensive Segmental Revision System

Launched by ZIMMER BIOMET · Aug 31, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment system called the Comprehensive Segmental Revision System, designed to help people with joint problems caused by conditions like degenerative diseases, rheumatoid arthritis, and issues following surgeries. The goal is to evaluate how well this system works and what the clinical outcomes are for patients who need revision surgery, which means surgeries performed to fix or improve previous surgeries that didn’t work as expected.

To participate in this trial, candidates must have specific joint issues, such as osteoarthritis or rheumatoid arthritis, and may have experienced failed previous treatments. Unfortunately, individuals currently dealing with active infections or certain serious conditions won’t be eligible. If you join the study, you can expect to receive care that focuses on improving your joint function and quality of life. The trial is currently looking for participants of all ages and genders, so if you meet the criteria, you might be able to help advance medical knowledge while receiving potentially beneficial treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Non Inflammatory Degenerative joint disease, including osteoarthritis, and avascular necrosis
• • Rheumatoid arthritis
• • Revision where other devices or treatments have failed
• • Correction of functional deformity
• • Oncology applications including bone loss due to tumour resection
• Exclusion Criteria:
• • Sepsis ( active)
• • Infection ( active)
• • Osteomyelitis (active)